Global medical supply chains are among the most complex and interdependent systems in the modern world, linking raw material producers, manufacturers, distributors, and healthcare providers across multiple continents. This interdependence has historically enabled efficiency, cost reduction, and broad access to life-saving medicines and technologies. However, recent geopolitical tensions, coupled with the lessons of the COVID-19 pandemic, have revealed that this interconnectedness is also a source of profound vulnerability. As global politics grow more fragmented, medical supply chains are increasingly under strain, forcing policymakers and industry leaders to reconsider how resilience, security, and equity can be balanced in the future.
The COVID-19 pandemic marked a turning point in how medical supply chains are understood. During the early phases of the crisis, countries around the world experienced acute shortages of personal protective equipment (PPE), ventilators, diagnostic tests, and essential medicines. Nearly 90% of countries reported disruptions in access to critical medical supplies, exposing the fragility of systems built on efficiency and just-in-time production models. These shortages were not merely logistical failures but reflections of deeper structural issues, including heavy reliance on a small number of manufacturing hubs and limited redundancy in supply networks.
At the heart of the problem lies globalization itself. Over the past several decades, the production of pharmaceuticals and medical devices has become highly geographically concentrated. Although the U.S. pharmaceutical industry still dominates the global market, accounting for roughly 50% of global pharmaceutical sales revenue, emerging economies such as Brazil, China, and India are rapidly becoming key pharmaceutical markets. Active pharmaceutical ingredients (APIs), for example, are often manufactured in these countries, while final drug production may occur elsewhere. This fragmentation creates efficiencies but also introduces multiple points of failure. When one node in the chain is disrupted, whether by a factory shutdown, export restriction, or transportation bottleneck, the effects ripple globally.
Canada’s pharmaceutical system reflects this broader pattern of interdependence. From 2018 to 2022, pharmaceutical imports increased by 55%, underscoring a growing reliance on international supply. India and China alone supplied over 60% of raw materials and APIs to Canada, while the United States remains its most significant trading partner, accounting for 64% of pharmaceutical exports and 29% of imports. While these relationships enable stable access under normal conditions, they also heighten vulnerability to external shocks.
Geopolitics has further amplified these risks. Trade tensions, export controls, and regional conflicts increasingly shape the flow of medical goods. Governments may impose export bans during crises to secure domestic supply, as seen during the pandemic and in subsequent disruptions. Such measures, while politically understandable, can exacerbate shortages elsewhere and undermine global coordination. More recently, conflicts affecting critical trade routes have demonstrated how quickly disruptions can spread.
For instance, the U.S.-Iran conflict and ongoing disruptions to air cargo and the Strait of Hormuz threaten key shipping corridors through which an estimated 10-20% of global pharmaceutical trade passes. Although the conflict has not yet led to any U.S. drug shortages, persisting cargo backlogs bring the threat of higher prices for generic drugs and spot shortages, especially in developing countries. In fact, roughly a third of the world’s helium supply – a critical component of medical imaging – is currently in limbo. Furthermore, many medicines and medical products have to be transported in temperature-controlled settings and any delays or deviations from this can lead to the products going bad, or being unsuitable for patient use.
In addition to conflict, economic nationalism and shifting trade policies are also reshaping supply chain strategies. Tariffs and regulatory barriers have increased costs and incentivized companies to reconsider their sourcing and manufacturing locations. However, efforts to “reshore” or localize production are not straightforward. Medical manufacturing often requires specialized infrastructure, regulatory approvals, and highly skilled labor, making rapid relocation difficult and expensive. As a result, while diversification is a growing priority, complete decoupling from global networks is neither feasible nor desirable.
The consequences of these geopolitical pressures are already visible in healthcare systems worldwide. Reports of shortages, from basic pain medications to specialized surgical materials, highlight how fragile supply chains remain. These shortages can delay treatments, increase healthcare costs, and ultimately compromise patient outcomes. In some cases, reliance on a limited number of overseas suppliers creates critical “pinch points,” where disruptions in a single region can halt access to essential drugs entirely.
Yet, interdependence is not inherently negative. Global supply chains enable the pooling of resources, expertise, and production capacity in ways that no single country could achieve alone. The challenge, therefore, is not to dismantle interdependence but to manage it more effectively. This requires a shift from prioritizing efficiency alone to incorporating resilience, transparency, and adaptability as core design principles.
One key strategy is diversification. Expanding the number of suppliers and geographic locations involved in production can reduce reliance on any single source. This approach, however, must be balanced against cost considerations and regulatory complexity. Another critical measure is improving supply chain visibility. Enhanced data sharing and digital tracking systems can help stakeholders anticipate disruptions, monitor inventory levels, and respond more quickly to emerging shortages.
Stockpiling and strategic reserves also play an important role, particularly for essential medicines and equipment. Governments and healthcare systems are increasingly recognizing the need to maintain buffer stocks to absorb shocks. However, stockpiling must be carefully managed to avoid waste, especially for products with limited shelf lives.
International cooperation remains essential. Despite rising geopolitical tensions, global health challenges require coordinated responses. Initiatives such as multinational procurement mechanisms and collaborative manufacturing agreements can help ensure more equitable access to medical supplies during crises. At the same time, partnerships between governments and the private sector are crucial for aligning incentives and mobilizing resources effectively.
Ultimately, the future of medical supply chains will be shaped by a delicate balance between globalization and strategic autonomy. Complete self-sufficiency is unrealistic for most countries, but excessive dependence on external suppliers poses significant risks, especially in times of global economic chaos. The goal, therefore, is to build “resilient interdependence”, a system in which global networks are maintained but reinforced with safeguards against disruption.
The strain on medical supply chains further reflects broader shifts in the global geopolitical landscape. The pandemic exposed fundamental weaknesses, while ongoing tensions continue to test the system’s resilience. By rethinking how interdependence is structured and governed, it is possible to build medical supply chains that are not only more robust but also better equipped to meet the health challenges of an increasingly uncertain world.
Image credit: Vitamins Pills Pharmacy (published 18 December 2022), depicting assorted vitamins and pills, by Ri_Ya via Pixabay. Licensed under the Pixabay Content License.
Disclaimer: Any views or opinions expressed in articles are solely those of the author and do not necessarily represent the views of the NATO Association of Canada.
